Aug 2026· Journal of Cardiology· 0 citations· 41 references
Medicine
TL;DR
Current evidence supports FAI/FAI-Score primarily as a prognostic marker; trial-level evidence that FAI-guided management decisions improve patient outcomes is not yet available, and substantial technical challenges remain.
Abstract
Pericoronary adipose tissue (PCAT) imaging has emerged as a promising noninvasive marker of coronary inflammation and an adjunctive risk-stratification tool beyond conventional coronary computed tomography angiography (CCTA) findings such as luminal stenosis and plaque morphology. The fat attenuation index (FAI), derived from CCTA, quantifies phenotypic changes in pericoronary fat driven by vascular inflammation. The CRISP-CT study demonstrated that elevated FAI around the right coronary artery independently predicted cardiac mortality. The ORFAN study further established that the FAI-Score-an artificial intelligence-adjusted derivative of raw PCAT attenuation-predicts cardiac events even in the absence of obstructive coronary artery disease. Multiple meta-analyses have consistently demonstrated that elevated PCAT attenuation is associated with an increased risk of major adverse cardiovascular events. It should be emphasized, however, that current evidence supports FAI/FAI-Score primarily as a prognostic marker; trial-level evidence that FAI-guided management decisions improve patient outcomes is not yet available. Beyond established prognostic applications, investigational uses include the identification of functionally significant lesions, acute coronary syndrome mechanism characterization, vasospastic angina prediction, myocardial infarction with non-obstructive coronary arteries assessment, treatment-response monitoring, and risk stratification in diabetic populations; these emerging applications require prospective validation. The fat radiomic profile, a machine-learning-derived extension, captures structural remodeling in pericoronary fat that persists beyond the acute inflammatory changes detected by FAI alone. However, substantial technical challenges remain. Reconstruction algorithms and tube voltage introduce measurement variability that can exceed the biological signal, and no major cardiovascular society has issued formal recommendations for routine clinical use. This review provides an overview of the biological rationale, measurement methodology, prognostic evidence, emerging and investigational applications, and current limitations of PCAT-based coronary inflammation imaging.
A vendor‐neutral reporting and validation framework is proposed and PCAT biomarkers are position as complementary to coronary calcium, stenosis, plaque phenotype, CT‐derived physiology, and artificial intelligence–assisted risk stratification rather than as a hierarchy of prognostic tests.
V. Hoang, V. Chansomphou, C. Trinh· BioMed Research Internationa...· 0 citations
Background: Coronary artery disease remains the leading cause of morbidity and mortality worldwide. Increasing evidence has demonstrated that many acute coronary events originate not from severely obstructive lesions but from structurally unstable atherosclerotic plaques. Consequently, the identification of vulnerable...
A. Nedelcu, Emil Anton, Ancuța Lupu et al.· Medical Science· 0 citations
CCTA is evolving into a multidimensional phenotyping tool for NOCA; its immediate value is refined risk stratification; whether these markers will improve outcomes remains unproven and should be tested prospectively.
P. Piña, A. Filtz, Daniel Lorenzatti et al.· Current Opinion in Cardiolog...· 0 citations
Coronary perivascular FAI is an independent imaging marker for CT-FFR-defined functional ischemia and provides incremental value beyond traditional risk factors and EAT volume, support FAI as a non-invasive marker of coronary inflammation that may refine risk stratification for functionally significant coronary artery...
Zhi-Hong Gao, Lin-Hui Jia, Min Jia· Frontiers in Cardiovascular...· 0 citations
Whether the traditional stenosis-centered approach remains sufficient for risk stratification and clinical decision-making is explored and how contemporary imaging modalities, coronary physiology, and artificial intelligence contribute to a more comprehensive assessment of coronary atherosclerosis is discussed.
C. R. Costantini, J. F. Franchini Ramires, M. Denk et al.· Current Cardiology Reports· 0 citations
Carotid PVAT attenuation was not associated with symptomatic culprit lesions or histological and molecular markers of plaque inflammation and vulnerability, and was not associated with thinner fibrous cap or higher plaque levels of pro-inflammatory cytokines.
S. Mayrhofer, L. Živković, Y. Li et al.· medRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.